secwatch.observer — SEC 8-K summary
======================================

Issuer:     OnKure Therapeutics, Inc. (OKUR)
CIK:        0001637715
Form:       8-K
Filed at:   2021-10-12T23:59:59+00:00
Accession:  0001193125-21-296205
Event type: leadership
Sentiment:  positive
Materiality: 0.50
Item codes: 5.02
LLM model:  deepseek-v4-flash:cloud@v2

Reneo Pharma appoints Ashley F. Hall as Chief Development Officer
-----------------------------------------------------------------

- Hall previously CDO at Esperion; oversaw regulatory for NEXLETOL, NEXLIZET, and REPATHA.
- Base salary $420,000, bonus up to 40%, housing reimbursement up to $5,000/month.
- Relocation assistance of $150,000 if relocated within 18 months.
- Equity inducement: option for 180,000 shares (4-yr vest) and RSU for 30,000 shares (vests on first NDA/MAA).
- Severance: 9 months base/COBRA; on change in control 12 months plus full equity acceleration.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/0001193125-21-296205-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1637715/000119312521296205/d239269d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-21-296205

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer